---
schema_version: "secwatch.filing_event.v1"
accession: "0001663577-24-000257"
form_type: "8-K"
ticker: "SKVI"
cik: "0001085277"
company_name: "SKINVISIBLE, INC."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:06:57.237676+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Skinvisible announces 99.6% transdermal penetration of GLP-1 drug in preclinical study

## Summary
- GLP-1 drug danuglipron formulated with Invisicare showed 99.6% penetration over 6 hours in Franz cell diffusion studies.
- CB-1 antagonist formulated with Invisicare showed 62% penetration over 6 hours; sustained delivery with no initial spike.
- Company is developing other GLP-1 agonists and CB-1 antagonists for transdermal obesity treatment.
- Seeking strategic partnerships to bring first transdermal obesity therapies to market.
- Obesity drug market projected to reach $105B-$144B by 2030 per Morgan Stanley.

## SEC filing metadata
- accession: 0001663577-24-000257
- form_type: 8-K
- ticker: SKVI
- cik: 0001085277
- company_name: SKINVISIBLE, INC.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1085277/000166357724000257/0001663577-24-000257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1085277/000166357724000257/skvi8k_100324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001663577-24-000257
- JSON: https://secwatch.observer/filing/0001663577-24-000257.json
- Plain text: https://secwatch.observer/filing/0001663577-24-000257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.